Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia

OBJECTIVES: Chelating agents remain the mainstay in reducing the iron burden and extending patient survival in homozygous beta-thalassemia but adverse and toxic effects may increase with the institution and long term use of this essential therapy. This study aimed to estimate the incidence of defera...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Al-Khabori, Murtadha, Bhandari, Sunil, Al-Huneini, Mohammed, Al-Farsi, Khalil, Panjwani, Vinodh, Daar, Shahina
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: OMJ 2013
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3628199/
https://ncbi.nlm.nih.gov/pubmed/23599881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5001/omj.2013.31
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg